

Cytheris initiates Phase I Clinical Trial of its first recombinant protein, CYT 99 007, and expands its Board.

Vanves, France, January 12, 2004. After FDA approval of its IND application, Cytheris announces the entry of its first recombinant protein in a phase one clinical study.

CYT 99 007 is a recombinant human Interleukin-7 developed by Cytheris. This cytokine targets the immune reconstitution of immuno-compromised patients, undergoing cancer treatment, affected by AIDS, or recovering from a bone marrow transplant.

This first phase I is performed in Bethesda (MD, USA), in cooperation with National Cancer Institute Investigators. The clinical trial, including oncology patients, will evaluate the safety, the immune effects and various surrogate markers of clinical activity, according to a classical dose escalation design. This first move will soon be complemented by additional Phase I/II trials targeting other patient populations.

The Cytheris board, composed of the Bioam Investment Fund represented by Chantal Parpex, and two of the co-founders, Etienne Bouillot and Michel Morre (company chairman and CEO), welcomes two new members who will provide additional expertise through this scale up period:

Jean-Jacques Bertrand, an experienced executive of the Pharma Industry, ex chairman of Aventis Pasteur and currently chairman of CANVAC ,

And Philippe Masson, a specialist of corporate governance and business transformation, ex leader of the strategic consulting profession at Cap Gemini Ernst & Young and currently chairman of Performance Management Associates.

About Cytheris

Based in Vanves, France and in Rockville, Maryland USA, Cytheris (**CY**tokine **THER**apy for the **I**mmune **S**ystem) is a French Biotechnology company focused on the development of new therapies for the immune system. Its primary area of interest targets global and specific immune reconstitution.

Contacts:

Cytheris SA
21 rue Aristide Briand
92170 VANVES France
Tel : 33 1 58 88 38 00
info@cytheris.com